File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: A phase I study of pazopanib in patients with advanced hepatocellular carcinoma

TitleA phase I study of pazopanib in patients with advanced hepatocellular carcinoma
Authors
Yau, CCChen, PJCurtis, CMMurphy, PSSuttle, ABArumugham, THodge, JPDar, MMPoon, R
KeywordsMedical sciences
Oncology medical sciences
Radiology and nuclear medicine pharmacy and pharmacology biology
Cytology and histology
Issue Date2009
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
The 45th Annual Meeting of the American Society of Clinical Oncology (ASCO 2009), Orlando, FL., 29 May-2 June 2009. In Journal of Clinical Oncology, 2009, v. 27 n. 15 suppl. (May 20), abstract no. 3561 How to Cite?
AbstractBACKGROUND: Patients (pts) with advanced hepatocellular carcinoma (HCC) have a poor prognosis. HCC is a highly vascular tumor with increased levels of angiogenic factors including VEGF and VEGFR. Pazopanib (GW786034 ) is an oral angiogenesis inhibitor targeting VEGFR, PDGFR, and c-Kit. A Phase I study was conducted to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics and efficacy of pazopanib in patients with locally unresectable and/or …
DescriptionThis journal suppl. contain 2009 ASCO Meeting Abstracts
Open Access Journal
Persistent Identifierhttp://hdl.handle.net/10722/186803
ISSN
0732-183X
2021 Impact Factor: 50.717
2020 SCImago Journal Rankings: 10.482

 

DC FieldValueLanguage
dc.contributor.authorYau, CCen_US
dc.contributor.authorChen, PJen_US
dc.contributor.authorCurtis, CMen_US
dc.contributor.authorMurphy, PSen_US
dc.contributor.authorSuttle, ABen_US
dc.contributor.authorArumugham, Ten_US
dc.contributor.authorHodge, JPen_US
dc.contributor.authorDar, MMen_US
dc.contributor.authorPoon, Ren_US
dc.date.accessioned2013-08-20T12:21:03Z-
dc.date.available2013-08-20T12:21:03Z-
dc.date.issued2009en_US
dc.identifier.citationThe 45th Annual Meeting of the American Society of Clinical Oncology (ASCO 2009), Orlando, FL., 29 May-2 June 2009. In Journal of Clinical Oncology, 2009, v. 27 n. 15 suppl. (May 20), abstract no. 3561en_US
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/186803-
dc.descriptionThis journal suppl. contain 2009 ASCO Meeting Abstracts-
dc.descriptionOpen Access Journal-
dc.description.abstractBACKGROUND: Patients (pts) with advanced hepatocellular carcinoma (HCC) have a poor prognosis. HCC is a highly vascular tumor with increased levels of angiogenic factors including VEGF and VEGFR. Pazopanib (GW786034 ) is an oral angiogenesis inhibitor targeting VEGFR, PDGFR, and c-Kit. A Phase I study was conducted to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics and efficacy of pazopanib in patients with locally unresectable and/or …-
dc.languageengen_US
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/-
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectRadiology and nuclear medicine pharmacy and pharmacology biology-
dc.subjectCytology and histology-
dc.titleA phase I study of pazopanib in patients with advanced hepatocellular carcinomaen_US
dc.typeConference_Paperen_US
dc.identifier.emailYau, CC: tyaucc@hku.hken_US
dc.identifier.emailPoon, R: poontp@hku.hken_US
dc.identifier.authorityYau, CC=rp01466en_US
dc.identifier.authorityPoon, R=rp00446en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros217024en_US
dc.identifier.volume27en_US
dc.identifier.issue15 suppl. (May 20)en_US
dc.publisher.placeUnited States-
dc.customcontrol.immutablesml 131007-
dc.identifier.issnl0732-183X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats